La catena delle opzioni mostra i dati chiave delle opzioni azionarie di TELA Bio a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per TELA Bio..

TELA Bio (NASDAQ:TELA) Azioni, Catena delle Opzioni

TELA Bio

TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.

TELA Bio Inc

Teladoc Health Inc

WIIM

VSEC

VSE shares are trading higher after the company reported better-than-expected Q2 financial results and issued FY25 sales guidance above estimates.

NV5 Global, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/NVEE#NASDAQ">NVEE</a>) ("NV5" or the "Company"), a leading provider of tech-enabled engineering, testing, inspection, and consulting solutions for the built environment, announced today that holders of a majority of its outstanding common stock voted to approve the proposed merger (the "Merger") with Acuren Corporation ("Acuren") at a Special Meeting of Stockholders (the "Special Meeting") held today.
Under the terms of the Agreement and Plan of Merger dated as of May 14, 2025 relating to the Merger, NV5 stockholders will receive approximately $23.00 per share consisting of $10.00 in cash and $13.00 in shares of Acuren common stock at closing, subject to potential adjustment as a result of a 10% collar feature. Upon consummation of the Merger, pre-Merger NV5 stockholders are expected to collectively own up to approximately 40% of the common stock of the combined company on a pro forma basis. Pre-Merger Acuren stockholders are expected to collectively own approximately 60% of the common stock of the combined company on a pro forma basis. The transaction is subject to customary closing conditions, and is expected to close promptly in August 2025.

NVEE

NV5 Shareholders Approve Merger With Acuren; Stockholders To Receive $23/Share, Consisting Of $10.00 In Cash And $13.00 In Shares

Shares of Psyence Biomedical Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) are surging Thursday morning following an announcement from the company and its strategic partner, PsyLabs. 
What To Know: The companies <a href="https://www.benzinga.com/pressreleases/25/07/g46752439/psyence-biomeds-strategic-collaboration-with-psylabs-yields-breakthrough-in-high-purity-ibogaine-p">reported</a> the successful production of a high-purity, GMP-aligned Ibogaine Total Alkaloid extract, a significant milestone in the field of psychedelic medicine.
According to the release, the naturally derived extract was verified by an accredited third-party laboratory to have met all microbial safety standards for food-grade consumption. 
The company says this achievement validates Psyence BioMed's strategic investment in PsyLabs. Psyence BioMed first acquired an equity stake in the producer in 2024 and expanded its investment in 2025.
Psyence BioMed, the <a href="https://www.benzinga.com/pressreleases/25/07/g46752439/psyence-biomeds-strategic-collaboration-with-psylabs-yields-breakthrough-in-high-purity-ibogaine-p">breakthrough</a> is a crucial step toward creating a reliable supply of scalable, compliant and ethically sourced psychedelic Active Pharmaceutical Ingredients. 
PsyLabs officials confirmed their commitment to refining processes to achieve even higher purity levels and are currently expanding production capacity to meet growing global demand.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, PBM shares are trading higher by 2.6% to $5.52 Thursday morning. The stock has a 52-week high of $364.63 and a 52-week low of $2.92.
Read Also: <a href="https://www.benzinga.com/news/health-care/25/07/46755354/soligenix-drug-matches-fda-approved-amgen-therapy-in-rare-inflammatory-disease">Soligenix Drug Matches FDA-Approved Amgen Therapy In Rare Disease Trial</a>
<h2 class="wp-block-heading">How To Buy PBM Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Psyence Biomedical&#8217;s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Image: Shutterstock

News

Psyence BioMed (PBM) Shares Soar On Ibogaine Production Breakthrough

Ferrari N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RACE#NYSE">RACE</a>) reported second-quarter financial results before the market open on Thursday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/07/g46751073/keep-on-delivering-robust-results-in-q2-2025-stronger-confidence-in-full-year-guidance">of the report</a>.
Q2 Earnings: Ferrari reported second-quarter revenue of $2.03 billion, beating analyst <a href="http://benzinga.com/quote/RACE/earnings">estimates</a> of $1.82 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company reported second-quarter earnings of $2.70 per share, beating estimates of $2.39 per share. 
Total revenue was up 4.4% year-over-year on shipments of 3,494 units in the quarter. Revenue from cars and spare parts was up 2.3% year-over-year and sponsorship, commercial and brand revenue climbed 21.9% year-over-year. 
&#8220;The first semester of 2025 reminded us once more about the importance of agility and flexibility in the management of our Company. Today&#8217;s strong results reflect our commitment to execute our strategy with discipline and focus. We continue to drive innovation and enrich our product portfolio, which fuels an already strong order book,&#8221; said Benedetto Vigna, CEO of Ferrari.
On the conference call following the print, Vigna reportedly said the company expects deliveries for the rest of 2025 to be deliberately reduced versus 2024 as Ferrari prioritizes quality of revenue over volume.
Ferrari expects full-year 2025 earnings to be greater than $9.75 per share versus estimates of $8.96 per share. 
RACE Price Action: <a href="http://benzinga.com/quote/RACE">Ferrari shares</a> were down 11.6% at $440.83 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46740005/ford-q2-earnings-revenue-eps-beat-estimates-shares-slide-as-automaker-warns-of-2-billion-tariff-headwind">Ford Q2 Earnings: Revenue, EPS Beat Estimates, Shares Slide As Automaker Warns Of $2 Billion Tariff Headwind</a></li>
</ul>
Photo: Sue Thatcher/Shutterstock.com

Earnings

Movers

RACE

Ferrari Stock Slides On Q2 Earnings: The Details

Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Overweight and raises the price target from $150 to $158.

Price Target

Analyst Ratings

NBIX

Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $158

Howmet Aerospace Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) announced its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46751567/howmet-aerospace-reports-second-quarter-2025-results" rel="noreferrer noopener">second-quarter 2025</a> financial results on Thursday. The company exceeded all guidance and strengthened its position in the aerospace and defense sectors.
The company reported record revenue and profit, driven by robust demand, prompting an upward revision of its full-year 2025 outlook.
Howmet Aerospace achieved record revenue of $2.05 billion, a 9% year-over-year increase, fueled by strong growth in commercial aerospace (up 8%), defense aerospace (up 21%), and industrial and other markets (up 17%), surpassing consensus estimates of $2.007 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/07/46495031/howmet-aerospace-stock-hits-all-time-highs-analysts-eye-further-gains" rel="noreferrer noopener">Howmet Aerospace Stock Hits All-Time Highs, Analysts Eye Further Gains</a>
Net Income reached $407 million, or $1.00 per share. Adjusted earnings per share rose 36% year over year to 91 cents, beating <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">the consensus estimate of 87 cents</a>.
Adjusted EBITDA (excluding special items) surged 22% to $589 million, with the margin expanding 300 basis points to 28.7%. Adjusted operating income margin expanded 330 bps to 25.3%.
The company generated a record $344 million in free cash flow, marking its ninth consecutive positive quarter. Operating cash flow totaled $446 million, with a quarter-end cash balance of $546 million.
In the second quarter, Engine Products led segment performance with a 13% year-over-year revenue increase to $1.1 billion, fueled by strength in aerospace, industrial gas turbines, and the oil and gas markets. The segment delivered a 20% rise in adjusted EBITDA, reaching $349 million, representing a healthy margin of 33.0%.
Fastening Systems followed with a 9% revenue increase to $431 million, supported by robust demand in both commercial and defense aerospace. Adjusted EBITDA for the segment climbed 25% to $126 million, translating to a margin of 29.2%.
Engineered Structures saw revenue grow 5% to $290 million, primarily driven by gains in defense aerospace. The segment&#8217;s adjusted EBITDA surged 55% to $62 million, reflecting a margin of 21.4%, the strongest year-over-year EBITDA growth among all divisions.
Meanwhile, Forged Wheels was the only segment to post a decline in revenue, which edged down 1% to $276 million due to softer commercial transportation volumes. However, this was partially offset by favorable aluminum cost pass-throughs. Despite the top-line pressure, the segment&#8217;s adjusted EBITDA rose 1% to $76 million, yielding a 27.5% margin.
Howmet Aerospace repurchased $175 million of common stock in the quarter and an additional $100 million in July 2025. Year-to-date, $400 million in stock has been repurchased, with $1.797 billion remaining under authorization.
The Board increased the quarterly common stock dividend by 20% to 12 cents per share, to be paid on August 25, 2025, to holders of record as of the close of business on August 8, 2025
The company also paid down $76 million of its U.S. dollar-denominated Term Loan, reducing annualized interest expense and bringing the net debt-to-LTM EBITDA ratio to a record low of 1.3x.
Howmet Aerospace Executive Chairman and Chief Executive Officer John Plant commented, &#8220;Turning to the outlook, the commercial aerospace market should continue to grow, driven by healthy passenger traffic, extraordinarily high OEM backlogs and the desire for new, fuel-efficient aircraft. We acknowledge positive signs for narrow body build rate increases, particularly on the Boeing 737MAX. Demand for engine spares also remains robust across all markets. The defense aerospace market continues to show strength that should carry through 2025.&#8221;
&#8220;Additionally, demand for industrial gas turbines fueled by significant data center expansion should remain strong for the balance of the year. The commercial transportation market remains weak. Taking these factors into account, the overall picture appears healthy, and we are increasing our full year 2025 guidance on all metrics.&#8221;
<h2 class="wp-block-heading">Outlook</h2>
For the third quarter, the company expects revenue between $2.02 billion and $2.04 billion versus the consensus of $2.027 billion, with adjusted earnings per share projected between 89 and 91 cents versus <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">the consensus of 87 cents</a>. Adjusted EBITDA is forecast between $575 million and $585 million, representing a margin of 28.5% to 28.7%.
The company raised its full-year 2025 outlook, now expecting revenue of $8.08 billion to $8.18 billion, up $100 million from the prior baseline versus the consensus of $8.084 billion. Adjusted EPS is projected at $3.56 to $3.64, a 20-cent increase versus the consensus of $3.51.
Adjusted EBITDA is guided between $2.3 billion and $2.34 billion, up $70 million, with a margin of approximately 28.5% to 28.6%, up 50 basis points. Free cash flow is now expected to range from $1.175 billion to $1.275 billion, an increase of $75 million.
Price Action: HWM shares are trading lower by 6.53% to $179.75 at Thursday&#8217;s last check.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46759415/norwegian-cruise-line-sees-record-advance-ticket-sales-reaffirms-profit-outlook" target="_blank" rel="noreferrer noopener">Norwegian Cruise Line Sees Record Advance Ticket Sales, Reaffirms Profit Outlook</a></li>
</ul>
Photo by T. Schneider via Shutterstock

Guidance

Howmet Aerospace Posts Record Profit, Raises 2025 Outlook

Morgan Stanley analyst Jefferson Harralson maintains Navient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAVI#NASDAQ">NAVI</a>) with a Equal-Weight and lowers the price target from $15 to $14.

NAVI

Morgan Stanley Maintains Equal-Weight on Navient, Lowers Price Target to $14

RBC Capital analyst Matthew Swanson maintains Magnite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>) with a Outperform and raises the price target from $19 to $27.

MGNI

RBC Capital Maintains Outperform on Magnite, Raises Price Target to $27

FMC shares are trading lower after the company reported Q2 financial results and cut its FY25 sales guidance. UBS lowered its price target on the stock from $45 to $44.

Morgan Stanley analyst Simeon Gutman maintains Mister Car Wash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCW#NASDAQ">MCW</a>) with a Equal-Weight and lowers the price target from $9 to $7.5.

Morgan Stanley Maintains Equal-Weight on Mister Car Wash, Lowers Price Target to $7.5

Investor interest in cannabis stocks has cooled since the legalization boom of 2021, and the craft beer and wellness sectors have had their own struggles navigating changing consumer tastes. But Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) may be quietly carving out a position that makes it different from any of its peers.
Tilray ended fiscal 2025 with record revenue of $821 million, driven by its cannabis, beverage, and wellness divisions. The company remains Canada's top cannabis brand and saw international cannabis sales surge 71% in the latest quarter, showing strength in Europe, where regulation is evolving quickly.
But what sets Tilray apart is the way it's combining those businesses. Its craft beer acquisitions — Hop Valley Brewing, Terrapin Beer Co., Revolver Brewing, and Atwater Brewery — have given Tilray a U.S. distribution network that it's now leveraging to roll out hemp‑derived THC drinks. Those beverages are already on shelves in 13 states at roughly 1,300 locations, giving Tilray an early lead in a market segment that could accelerate if THC drink laws expand.
Other companies are circling this same convergence point, but none have fully committed. Canopy Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) and Curaleaf (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTCQX">CURLF</a>) have strong cannabis and CBD operations but aren't in beverages in a meaningful way. On the flip side, beverage players like Molson Coors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) are experimenting with THC drinks, but don't have cannabis cultivation or international wellness businesses.
Tilray is essentially the only scaled player weaving it all together under one roof.
The company did report a headline $2.1 billion GAAP loss for the year — a figure that might alarm casual investors — but nearly all of that came from a non‑cash goodwill write‑down tied to older acquisitions made when valuations assumed U.S. legalization would arrive sooner. Strip that out, and Tilray actually posted a modest adjusted profit and improved its cannabis gross margins by 700 basis points.
While cannabis stocks have been hammered in recent years, Tilray's multi‑pronged strategy could give it resilience and serve as a hedge on where the industry is going. If cannabis sales lag, Tilray still has its beer portfolio and hemp drinks. If U.S. legalization finally hits, it's sitting on a built-in distribution machine.
Looking ahead, the bullish case for Tilray may rest on several catalysts, including U.S. federal cannabis reform, state‑by‑state loosening of THC beverage rules, or even further acquisitions in the craft beer space. Any of those could give Tilray a first‑mover advantage in a market where most competitors are still stuck in a single lane.
The company isn't without risks — from shifting regulations to dilution concerns as it finances growth — but its approach to connecting cannabis, beverages, and wellness could ultimately be its differentiator. And for investors looking for a long‑term play in the sector, that uniqueness might be the very thing that makes Tilray worth watching.
Disclosure: This article is for informational purposes only and is not investment advice. The author does not hold any position in the securities mentioned at the time of publication and does not plan to initiate any positions in the next 72 hours.
Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga&#8217;s reporting and has not been edited for content or accuracy.

Cannabis

Equities

Opinion

Trading Ideas

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

TLRY

Tilray's Unique Strategy Could Make It A Winner As Cannabis, Beverages, And Wellness Mature

Tether (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDT</a>) on Thursday released its Q2 2025 attestation, showing the company added over $13.4 billion in USDT <a href="https://www.benzinga.com/25/01/43374889/tether-expands-usdt-stablecoin-to-bitcoin-and-lightning-network">during the quarter</a>.
What Happened: With more than $20 billion in net new issuance year-to-date, the total supply of USDT has risen to over $157 billion.
The <a href="https://tether.io/news/tether-issues-20b-in-usdt-ytd-becomes-one-of-largest-u-s-debt-holders-with-127b-in-treasuries-net-profit-4-9b-in-q2-2025-attestation-report/">report</a> shows that Tether&#8217;s total exposure to U.S. Treasuries climbed to $127 billion, including $105.5 billion in direct holdings and $21.3 billion held indirectly, up from roughly $119 billion in Q1.
This level of exposure places Tether among the world's largest holders of U.S. sovereign debt, rivaling even institutional investors and central banks.
Tether's net profit for the second quarter reached approximately $4.9 billion, with $3.1 billion of that attributed to recurring operational earnings. 
The remainder, roughly $1.8 billion, came from mark-to-market appreciation in its bitcoin and gold holdings. 
Combined with Q1 results, total net profit for the first half of 2025 now stands at $5.7 billion.
Shareholder capital remained steady at around $5.47 billion, supporting Tether&#8217;s long-term solvency. 
The attestation confirmed that Tether's total assets stood at $162.57 billion at the end of June, exceeding its $157.1 billion in liabilities, of which $157.1 billion were related to tokens issued.
Tether noted that proprietary investments in emerging sectors such as AI, energy, and communications are not counted as part of its token reserves. 
However, these ventures, led through Tether Investments and XXI Capital, continue to receive a growing share of Tether's retained earnings.
The firm reported that roughly $4 billion has already been deployed into U.S.-based ventures as part of its reinvestment strategy, including projects like Rumble and the Rumble Wallet. 
These initiatives are aimed at enhancing financial infrastructure, digital rights, and open-source platforms globally.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46754477/ethereum-etfs-treasury-companies-now-hold-over-32b-in-eth-heres-whats-driving-the-frenzy">Ethereum ETFs, Treasury Companies Now Hold Over $32B In ETH: Here&#8217;s What&#8217;s Driving The Frenzy</a>
What&#8217;s Next: CEO Paolo Ardoino emphasized growing confidence in Tether's model, stating, "Q2 2025 affirms what markets have been telling us all year: trust in Tether is accelerating."
"With over $127 billion in U.S. Treasury exposure, robust Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and gold reserves, and over $20 billion in new USDT issued, we're not just keeping pace with global demand, we're shaping it,&#8221; he added.
Ardoino also noted that Tether represents a "live, proven model" of stablecoin functionality at scale, offering "transparency, resilience, and massive global reach" amid ongoing regulatory developments concerning digital dollars.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46753720/97-of-bitcoin-wallets-are-now-in-profit-what-does-it-mean-for-your-portfolio">97% Of Bitcoin Wallets Are Now In Profit — What Does It Mean For Your Portfolio?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$USDT

Tether Posts $4.9B Profit, Surpasses $127B In U.S. Treasuries In Q2

Morgan Stanley analyst Keith Weiss maintains Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) with a Overweight and raises the price target from $530 to $582.

MSFT

Morgan Stanley Maintains Overweight on Microsoft, Raises Price Target to $582

Benchmark Electronics shares are trading lower after the company issued Q3 GAAP EPS guidance below estimates.

Morgan Stanley analyst Kristine Liwag maintains Leonardo DRS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRS#NASDAQ">DRS</a>) with a Equal-Weight and raises the price target from $44 to $47.

Morgan Stanley Maintains Equal-Weight on Leonardo DRS, Raises Price Target to $47

Shares of AI infrastructure firm CoreWeave Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) are soaring in Thursday morning trading after receiving a vote of confidence from Citigroup.
The bank <a href="https://www.benzinga.com/quote/CRWV/analyst-ratings">upgraded</a> the stock to Buy from a previous Neutral rating and announced a new price target of $160, suggesting substantial upside and providing a powerful counter-narrative to recent bearish sentiment.
What To Know: The bullish call from Citi comes during a period of intense volatility for the stock, which has become a focal point of debate on Wall Street. 
Investors have been weighing the company's ambitious growth strategy, including its pending $9 billion all-stock <a href="https://www.benzinga.com/markets/tech/25/07/46423337/coreweave-6-billion-ai-bet-boosts-core-scientific-9-billion-deal">acquisition</a> of Core Scientific and a $6 billion plan for a new <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46410852/coreweave-commits-6-billion-to-us-ai-infrastructure-in-lancaster">AI data center</a>, against considerable risks.
Citi&#8217;s upgrade directly challenges the bearish case that has recently gained traction. Just last week, HSBC initiated coverage with a Reduce rating and a stark $32 price target, citing extreme customer concentration as its <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46503455/coreweave-shares-slide-after-hsbc-initiates-coverage-with-bearish-outlook">primary concern</a>. 
HSBC noted that a single client, Microsoft Corp, accounted for 72% of CoreWeave&#8217;s first-quarter revenue. That bearish call followed a string of downgrades in early July from firms worried about the high capital expenditures required for its expansion.
Thursday&#8217;s rally, sparked by the new analyst rating, underscores the ongoing tug-of-war between CoreWeave&#8217;s immense growth potential and its significant operational and financial risks, with Wall Street&#8217;s divided opinions acting as key catalysts for the stock&#8217;s direction.
Benzinga Edge Rankings: Based on financial data from <a href="http://benzinga.grsm.io/register174">Benzinga Edge</a>, CoreWeave&#8217;s market capitalization stands at approximately $55.61 billion. From a technical standpoint, the stock&#8217;s Relative Strength Index is at 41, suggesting it is in neutral territory and neither overbought nor oversold. 
Notably, short interest represents 7.13% of the stock&#8217;s float, with a &#8216;days to cover&#8217; ratio of 1.28, indicating a significant level of bearish bets against the company.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, CRWV shares are trading higher by 12.2% to $115.43 Thursday morning. The stock has a 52-week high of $187.00 and a 52-week low of $33.52.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46755987/applied-digital-stock-is-surging-thursday-whats-going-on">Applied Digital Stock Is Surging Thursday: What&#8217;s Going On?</a>
<h2 class="wp-block-heading">How To Buy CRWV Stock</h2>
By now you're likely curious about how to participate in the market for CoreWeave &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of CoreWeave, which is trading at $115.43 as of publishing time, $100 would buy you 0.87 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
Image: Shutterstock

CRWV

CoreWeave (CRWV) Stock Is Surging Thursday: What's Driving The Action?

Morgan Stanley analyst Joseph Moore maintains Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) with a Equal-Weight and raises the price target from $87 to $94.

LRCX

Morgan Stanley Maintains Equal-Weight on Lam Research, Raises Price Target to $94

GOOS

Canada Goose Holdings shares are trading lower after the company reported worse-than-expected Q1 adjusted EPS results.

RBC Capital analyst Matthew Hedberg downgrades CyberArk Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) from Outperform to Sector Perform and raises the price target from $420 to $448.

Downgrades

CYBR

RBC Capital Downgrades CyberArk Software to Sector Perform, Raises Price Target to $448

Wells Fargo analyst Larry Biegelsen maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Overweight and lowers the price target from $108 to $100.

Comments

TELA Bio

TELA Bio (TELA) Opzioni

TELA Bio (NASDAQ:TELA) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO